

Emergence of carbapenem-resistant ST131 *Escherichia coli* carrying *bla*_{OXA-244} in Germany, 2019 to 2020

Sybilie Welker¹, Sébastien Boutin², Thomas Miethke¹, Klaus Heeg², Dennis Nurjadi²

1. Institute for Medical Microbiology and Hygiene, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany

2. Medical Microbiology and Hygiene, Department of Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany

Correspondence: Dennis Nurjadi (dennis.nurjadi@uni-heidelberg.de)

Citation style for this article:

Welker Sybilie, Boutin Sébastien, Miethke Thomas, Heeg Klaus, Nurjadi Dennis. Emergence of carbapenem-resistant ST131 *Escherichia coli* carrying *bla*_{OXA-244} in Germany, 2019 to 2020. Euro Surveill. 2020;25(46):pii=2001815. <https://doi.org/10.2807/1560-7917.ES.2020.25.46.2001815>

Article submitted on 19 Oct 2020 / accepted on 18 Nov 2020 / published on 19 Nov 2020

The dissemination of carbapenem-producing Gram-negative bacteria is a major public health concern. We report the first detection of OXA-244-producing ST131 O16:H5 *Escherichia coli* in three patients from two tertiary hospitals in the south-west of Germany. OXA-244 is emerging in Europe. Because of detection challenges, OXA-244-producing *E. coli* may be under-reported. The emergence of carbapenem resistance in a globally circulating high-risk clone, such as ST131 *E. coli* is of clinical relevance and should be monitored closely.

Escherichia coli of the ST131 lineage is considered as a successful and emerging high-risk pandemic multidrug-resistant *E. coli* strain [1,2]. Typically, most ST131 *E. coli* are resistant to third-generation cephalosporins but remain susceptible to carbapenems [1]. We detected three OXA-244-producing ST131 *E. coli* from patient samples in two tertiary hospitals in the south-west of Germany between January 2019 and June 2020.

OXA-244 is a single-point mutation variant (Arg214Gly) of the globally circulating OXA-48 [3], resulting in lower minimum inhibitory concentration (MIC) values, which poses a major challenge for its detection [4,5].

The aim of our study was to investigate the genetic diversity of the emerging OXA-244-producing *E. coli* in the Rhine-Neckar region using whole-genome sequencing.

Local surveillance measures for multidrug-resistant organisms

Since January 2019, the University Hospitals in Heidelberg and Mannheim, located in the south-west of Germany (Rhine-Neckar region), have implemented routine molecular typing by whole-genome sequencing (WGS) of non-repetitive multidrug-resistant Gram-negative bacteria (MDR-GN) from admission screening and clinical samples as part of the local infection control measures. Admission rectal screening for MDR-GN

was performed for all risk patients, which includes (i) admission to intermediate and intensive care units, (ii) previous colonisation with multidrug-resistant organisms (MDRO) or contact with MDRO patients, (iii) contact with a high-prevalence setting or endemic region for MDRO (including travel and migration), (iv) chronic wounds and (v) close contact to animals, as previously described [6]. The cultural detection methods used a selective medium (ChromID ESBL, Biomérieux, Nürtingen, Germany) and were confirmed by antibiotic susceptibility testing (AST) with VITEK2 (Biomérieux) interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints v10.0 [7]. Carbapenemase genes were detected with an in-house PCR (data not shown) of all isolates with phenotypic resistance to carbapenem or with suspected carbapenem resistance (i.e. elevated MIC for carbapenems).

Only the first detected isolate from each patient was sequenced. Molecular characterisation was performed by short-read WGS using the Nextera DNA Flex Library Prep Kit (Illumina, San Diego, United States) and the MiSeq instrument (2 × 300 bp), as described previously [6]. Assembly was performed with Spades 3.13.0 [8]. Core genome was calculated using Roary [9] after annotation with Prokka 1.14.1 [10]. Coverage for each contig was extracted from the Spades output. Resistance genes were annotated using Abricate 1.0.0 with the database from the National Center for Biotechnology Information (NCBI) [11], the comprehensive antibiotic resistance database CARD [12], Antibiotic resistance gene-ANNOTation (ARG-ANNOT) [13] and Resfinder 3.0 [14] (latest update on 10 June 2020). Subtyping of the serotype and *fimH* was performed using SeroTypeFinder 2.0 (<https://cge.cbs.dtu.dk/services/SeroTypeFinder/>) and FimTyper 1.0 (<https://cge.cbs.dtu.dk/services/FimTyper/>). Assembled draft genome sequences are deposited in the NCBI GenBank database under the bioproject number PRJNA546126.

TABLE 1

Patient, clinical and microbiological characteristics of *bla*_{OXA-244} harbouring *Escherichia coli* in Heidelberg and Mannheim, Germany, 2019–2020 (n = 9)

Patient number	Patient characteristics				Clinical and microbiological characteristics									
	Accession number ^a	First detection	Detection on admission	Age group (years)	Migration / travel	Specimen ^b	Colonisation	Infection	Serotype ^c	MLST ^d	Carbapenemase	<i>fimH</i> ^e	Meropenem MIC (µg/mL) ^f	CIM
P1	SAMN16521172	Oct 2019	Yes	<10	No	Rectal swab	+	–	O16:H5	ST131	OXA-244	41	0.125 ^g	+
P2	SAMN16521173	Jan 2020	No	<10	No	Rectal swab, urine	+	+	O16:H5	ST131	OXA-244	41	0.75 ^g	+
P3	SAMN16521174	Dec 2019	No	≥70	Libyag	Rectal swab, urine, blood culture	+	+	O16:H5	ST131	OXA-244	41	6 ^g	+
P4	SAMN16521175	Sep 2019	Yes	40–50	Unknown	Rectal swab	+	–	O86:H14	ST38	OXA-244	–	0.5	+
P5	SAMN16521176	Dec 2019	Yes	40–50	No	Rectal swab	+	–	O86:H14	ST38	OXA-244	–	0.19	+
P6	SAMN16521177	Mar 2020	Yes	20–30	Unknown	Rectal swab	+	–	O102:H6	ST38	OXA-244	5	0.75	+
P7	SAMN16521178	May 2020	No	<10	No	Rectal swab	+	+	O153:H30	ST38	OXA-244	5	0.38	+
P8	SAMN16521179	Dec 2019	No	≥70	No	Rectal swab, urine	+	+	O86:H18	ST38	OXA-244	–	0.5	+
P9	SAMN16521180	Jul 2020	Yes	60–70	Unknown	Rectal swab	+	–	O101:H17	ST167	OXA-244 + NDM-5	–	4 ^h	+

CIM: carbapenem inactivation assay; MIC: minimum inhibitory concentration; MLST: multilocus sequence type; +: positive; –: negative.

^a Sequences were deposited in the Genbank at NCBI under the Bioproject PRINA546126.

^b First detection specimen is underlined, in cases with multiple samples. Only the first isolate of each patient was sequenced.

^c Serotype was derived from the assembled draft genome using the CGE Serotype Finder 2.0 (<https://cge.cbs.dtu.dk/services/SerotypeFinder/>).

^d MLST derived from the assembled draft genome using CGE FimTyper 1.0 (<https://cge.cbs.dtu.dk/services/FimTyper/>).

^e *fimH* typing was derived from the assembled draft genome using the CGE Serotype Finder V2.0.


^f Meropenem MIC was determined using an agar-based gradient diffusion test (E-test).

^g E-test exhibited slight growth within the zone of inhibition.

^h Patient was in Libya prior to detection of OXA-244 producing *E. coli*.

FIGURE 1

Antimicrobial resistance genes in OXA-244-producing *Escherichia coli* in the Rhine-Neckar region, Germany, 2019–2020 (n = 9)



ST: sequence type.

Black squares: presence, grey squares: absence of antimicrobial resistance genes; red font and red squares: carbapenemase genes.

TABLE 2
Antibiotic susceptibility profile of *bla*_{OXA-244}-harbouring *Escherichia coli* in the Rhine-Neckar region, Germany, 2019–2020 (n = 9)

Substance	ST131						ST38						ST167					
	P1		P2		P3		P4		P5		P6		P7		P8		P9	
	MIC	Int	MIC	Int	MIC	Int	MIC	Int	MIC	Int	MIC	Int	MIC	Int	MIC	Int	MIC	Int
Piperacillin/tazobactam	≥128	R	≥128	R	≥128	R	≥128	R	≥128	R	≥128	R	≥128	R	≥128	R	≥128	R
Cefotaxim	≥64	R	≥64	R	≥64	R	≥64	R	≥64	R	8	R	≥64	R	≥64	R	≥64	R
Ceftazidim	32	R	32	R	≥64	R	8	R	8	R	8	R	8	R	16	R	≥64	R
Cefepim	16	R	16	R	≥32	R	16	R	8	R	≤0.12	S	≥32	R	4	I	≥32	R
Ceftolozan/tazobactam	4	R	4	R	≥32	R	1	S	1	S	4	R	8	R	1	S	≥32	R
Imipenem	≤0.25	S	1	S	2	S	≤0.25	S	0.5	S	≤0.25	S	0.5	S	0.5	S	≥16	R
Meropenem	≤0.25	S	≤0.25	S	≥16	R	≤0.25	S	≤0.25	S	≤0.25	S	1	S	0.5	S	8	I
Ciprofloxacin	≤0.25	S	≤0.25	S	2	R	≤0.25	S	≤0.25	S	≤0.25	S	1	R	≤0.25	S	≥4	R
Trimethoprim/sulfamethoxazole	≥320	R	≥320	R	≤20	S	≤20	S	≥320	R	≥320	R	≥320	R	≥320	R	≥320	R
Gentamicin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	≥16	R	≥16	R	≤1	S	≥16	R
Tobramycin	≤1	S	≤1	S	≤1	S	≤1	S	≤1	S	4	R	≥16	R	≤1	S	8	R
Amikacin	2	S	2	S	2	S	2	S	2	S	2	S	2	S	≤1	S	2	S
Tigecyclin	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S
Aztreonam	≥64	R	≥64	R	≥64	R	16	R	16	R	2	I	16	R	16	R	≥64	R
Fosfomycin	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S	≤16	S
Colistin ^a	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S	≤0.5	S


I: intermediate; Int: interpretation; MIC: minimum inhibitory concentration in mg/L; R: resistant; S: susceptible; ST: sequence type.

MIC was determined by VITEK2 using the AST-N389 test panel. Antibiotic susceptibility was interpreted using the EUCAST clinical breakpoints v10.0 [7].

^a Interpretation and MIC for colistin using VITEK2 may not be reliable [28].

FIGURE 2

Genetic characteristics of *bla*_{OXA-244}-harbouring *Escherichia coli* in the Rhine-Neckar region, Germany, 2019–2020 (n = 9)



MLST: multilocus sequence type; SNP: single-nucleotide polymorphism.

A. Clustering by the genetic environment of the *bla*_{OXA-244} gene revealed two clusters. We were not able to identify any transposable elements within the contig of the assembled draft genome. Isolates belonging to the ST131 *E. coli* are indicated in red, ST38 in blue and ST167 in green font, corresponding to the figure legend of the minimum-spanning tree in panel C.

B. The analysis of the coverage in comparison to other contigs in the assembled draft genome suggests a chromosomal integration of the *bla*_{OXA-244} gene in almost all isolates. Red vertical bars represent the *bla*_{OXA-244}-containing contig.

C. Minimum-spanning tree based on the core genome of all sequenced *E. coli* in this study. Potential transmission clusters are indicated by the grey circles with SNP differences over the core genome in blue. There was no indication of patient-to-patient transmission (3,413 genes, 108,017 polymorphic sites). Numbers in square brackets indicate the number of isolates belonging to the MLST.

Molecular and microbiological characteristics of OXA-244-producing *Escherichia coli*

Between January 2019 and June 2020, we identified 50 *E. coli* with phenotypic carbapenem resistance, of which 41 carried a carbapenemase. Nine of the 41 carried *bla*_{OXA-244}, which belonged to three clonal lineages ST38 (n = 5), ST131 (n = 3) and ST167 (n = 1). The isolate belonging to ST167 harboured two carbapenemase genes, *bla*_{NDM-5} and *bla*_{OXA-244}. Relevant clinical and microbiological characteristics of the nine patients are summarised in Table 1.

The presence of genotypic antibiotic resistance determinants is summarised in Figure 1. Antibiotic susceptibility of all *bla*_{OXA-244} is displayed in Table 2. Isolates of the ST38 lineage carried variable extended-spectrum β -lactamase (ESBL) genes, such as *bla*_{CTX-M-14}, *bla*_{CTX-M-27} and *bla*_{TEM-1}, whereas all isolates of the ST131 clonal lineage harboured *bla*_{CTX-M-15} in addition to the *bla*_{OXA-244} gene (Figure 1).

Consistent with published data, the *bla*_{OXA-244} genes are most likely to have been integrated into the chromosome because sequencing coverage of the *bla*_{OXA-244}-containing contigs was lower than the overall average sequencing coverage (Figure 2A and 2B) [5,15].

Seven of nine isolates were susceptible to meropenem as indicated by the low MIC in two different AST methods (Tables 1 and 2). One isolate (ST167, P9) carried both *bla*_{OXA-244} and *bla*_{NDM-5} so that high MIC values for carbapenem were expected. However, the isolate from P3 exhibited an unusually high MIC for meropenem for an OXA-244 producer in both AST methods (≥ 16 mg/L in VITEK and 6 mg/L in E-test) (Tables 1 and 2), for reasons we could not explain. Nevertheless, all nine isolates exhibited positive results in the phenotypic carbapenem inactivation assay (CIM) using meropenem disk (10 μ g) with a 2 h inactivation step [16]. Our findings suggest that CIM may be a reliable method to detect OXA-244 producers and should be validated in further studies.

Potential origin and nosocomial transmission of OXA-244-producing ST131 *Escherichia coli*

SNP analysis to evaluate the clonal relationship of the isolates suggested two potential transmission clusters of patients P1–P2 with five SNP and P4–P5–P8 with 15–24 SNP (Figure 2C). Patient P1 was colonised with *bla*_{OXA-244} *E. coli* on admission. There was no recent travel exposure so that community acquisition in Germany was possible. P2 stayed in the same ward as P1 with some temporal overlap. P2 was born in the hospital and acquired the colonisation with ST131 OXA-244-producing *E. coli* during the hospital stay. Nosocomial transmission is a very likely source of acquisition as suggested by the identical genotypic and phenotypic resistance of both isolates of P1 and P2 (Figure 1 and Table 2). P3 was in a different hospital

than P1 and P2. The lack of epidemiological link is consistent with the genomic analysis, which did not indicate transmission. P3 had had contact with the healthcare system in Libya and was initially screened negative on admission in Germany. The *bla*_{OXA-244} *E. coli* was detected in subsequent screenings. However, we cannot fully rule out importation because the sensitivity of the detection method is limited [15].

In the ST38 cluster, there was no epidemiological overlap so that a nosocomial patient-to-patient transmission event is unlikely. Nevertheless, community transmissions caused by clonal dissemination of *bla*_{OXA-244}-positive ST38 *E. coli* in Germany cannot be entirely ruled out [17].

Discussion

The increased incidence in Europe of community-acquired infections with *E. coli* carrying OXA-244 is of public health relevance as reflected by the rapid risk assessment by the European Centre for Disease Prevention and Control (ECDC) at the beginning of 2020 [18]. Recently, several federal states in Germany reported a rise in detection of community-acquired infections with ST38 OXA-244-producing *E. coli* [17]. Similar observations have been reported in other European countries [4,5,19–21].

In Germany and other neighbouring countries in Europe, *bla*_{OXA-244} is predominantly found in ST38 *E. coli* [4,17,19,21,22]. Surveillance data from Denmark and France reported the presence of *bla*_{OXA-244} in other clonal groups (ST10, ST38, ST69, ST167, ST10, ST361 and ST 3268) [21,23], but to the best of our knowledge the presence of *bla*_{OXA-244} in ST131 *E. coli* in Europe has not been reported before. Besides being responsible for serious extra-intestinal infections, the development of resistance to carbapenems in the ST131 *E. coli* clonal lineage, is particularly worrisome as carbapenems are often the last line of therapy for life-threatening infections [2,24]. There are no systematic data on the prevalence of carbapenemase-producing Gram-negative bacteria in the Rhine-Neckar region. However, our data suggest a low prevalence of 0.5% (131/27,387 screened patients in the Heidelberg University Hospital in 2019), which is consistent with published data [25].

Peirano et al. reported that the global incidence of carbapenemase-producing *E. coli* ST131 O25b:H4 of the *fimH*₃₀/virotype C lineage is increasing, with *bla*_{KPC} as the most common carbapenem-resistance determinant [2]. In contrast, our *E. coli* ST131 has the serotype O16:H5 with *bla*_{OXA-244} that belongs to the *fimH*₄₁/virotype C lineage [26]. Although the major lineage of the highly virulent ST131 belongs to the serotype O25b:H4 and *fimH*₃₀, a murine infection model suggested that ST131 O16:H5 *fimH*₄₁ is comparable to the H30 lineage in virulence and lethality [27], which implies that the emergence of carbapenems resistance in the H41 ST131 lineage is equally relevant.

Our study has limitations, the detection of OXA-244 producing *E. coli* is a major diagnostic challenge owing to its low level of phenotypic resistance to carbapenems; therefore OXA-244 producers may be underreported. Nevertheless, our finding suggests that a simple phenotypic assay for carbapenem inactivation combined with routine WGS may be useful to detect low carbapenemase producers, such as OXA-244. In addition, the epidemiological data of our patients were limited so that the exact origin of the OXA-244-producing ST131 *E. coli* in this study cannot be fully elucidated.

Conclusion

The emergence and dissemination of virulent and dominant *E. coli* clones with resistance to last-line antibiotics is a public health concern. Our findings emphasise the necessity of adequate surveillance measures and warrant further studies on the epidemiology and transmission dynamics of carbapenem-resistant *E. coli* both in the hospital and community setting.

Ethical statement

Data and isolates were collected and characterised in accordance to the German Infection Protection Act. The local ethical committee was consulted for the usage of clinical data for scientific purposes and granted waiver of informed consent (S-474/2018).

Acknowledgements

We would like to thank Selina Hassel, Nicole Henny, Suzan Leccese and Delal Sahin for their excellent technical support.

Conflict of interest

None declared.

Authors' contributions

SW, SB, TM, KH, DN drafted and finalised the manuscript. SW, SB, DN performed the clinical data analysis and visualisation. SB performed the analysis of WGS data. All authors were involved in the design and conception of the study. All authors approved the final version of the manuscript.

References

- Nicolas-Chanoine MH, Bertrand X, Madec JY. *Escherichia coli* ST131, an intriguing clonal group. *Clin Microbiol Rev*. 2014;27(3):543-74. <https://doi.org/10.1128/CMR.00125-13> PMID: 24982321
- Peirano G, Bradford PA, Kazmierczak KM, Badal RE, Hackel M, Hoban DJ, et al. Global incidence of carbapenemase-producing *Escherichia coli* ST131. *Emerg Infect Dis*. 2014;20(11):1928-31. <https://doi.org/10.3201/eid2011.141388> PMID: 25340464
- Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. *J Antimicrob Chemother*. 2012;67(7):1928-31. <https://doi.org/10.1093/jac/dks121> PMID: 22499996
- Masseron A, Poirel L, Falgenhauer L, Imirzalioglu C, Kessler J, Chakraborty T, et al. Ongoing dissemination of OXA-244 carbapenemase-producing *Escherichia coli* in Switzerland and their detection. *Diagn Microbiol Infect Dis*. 2020;97(3):115059. <https://doi.org/10.1016/j.diagmicrobio.2020.115059> PMID: 32387849
- Potron A, Poirel L, Dortet L, Nordmann P. Characterisation of OXA-244, a chromosomally-encoded OXA-48-like β -lactamase from *Escherichia coli*. *Int J Antimicrob Agents*. 2016;47(1):102-3. <https://doi.org/10.1016/j.ijantimicag.2015.10.015> PMID: 26655033
- Kocer K, Boutin S, Dalpke AH, Heeg K, Muters NT, Nurjadi D. Comparative genomic analysis reveals a high prevalence of inter-species in vivo transfer of carbapenem-resistance plasmids in patients with haematological malignancies. *Clin Microbiol Infect*. 2020;26(6):780.e1-8. <https://doi.org/10.1016/j.cmi.2019.10.014> PMID: 31654794
- The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0, 2020. Available from: [http://www.eucast.org/clinical_breakpoints/\[REMOVED IF= FIELD\]](http://www.eucast.org/clinical_breakpoints/[REMOVED IF= FIELD])
- Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput Biol*. 2012;19(5):455-77. <https://doi.org/10.1089/cmb.2012.0021> PMID: 22506599
- Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, et al. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics*. 2015;31(22):3691-3. <https://doi.org/10.1093/bioinformatics/btv421> PMID: 26198102
- Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics*. 2014;30(14):2068-9. <https://doi.org/10.1093/bioinformatics/btu153> PMID: 24642063
- Feldgarden M, Brover V, Haft DH, Prasad AB, Slotta DJ, Tolstoy I, et al. Validating the AMRFinder tool and resistance gene database by using antimicrobial resistance genotype-phenotype correlations in a collection of isolates. *Antimicrob Agents Chemother*. 2019;63(11):e00483-19. <https://doi.org/10.1128/AAC.00483-19> PMID: 31427293
- Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. *Nucleic Acids Res*. 2017;45(D1):D566-73. <https://doi.org/10.1093/nar/gkw1004> PMID: 27789705
- Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, et al. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob Agents Chemother*. 2014;58(1):212-20. <https://doi.org/10.1128/AAC.01310-13> PMID: 24145532
- Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, et al. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother*. 2012;67(11):2640-4. <https://doi.org/10.1093/jac/dks261> PMID: 22782487
- Hoyos-Mallemot Y, Naas T, Bonnin RA, Patino R, Glaser P, Fortineau N, et al. OXA-244-producing *Escherichia coli* isolates, a challenge for clinical microbiology laboratories. *Antimicrob Agents Chemother*. 2017;61(9):e00818-17. <https://doi.org/10.1128/AAC.00818-17> PMID: 28674064
- Pierce VM, Simner PJ, Lonsway DR, Roe-Carpenter DE, Johnson JK, Brasso WB, et al. Modified carbapenem inactivation method for phenotypic detection of carbapenemase production among Enterobacteriaceae. *J Clin Microbiol*. 2017;55(8):2321-33. <https://doi.org/10.1128/JCM.00193-17> PMID: 28381609
- Kremer K, Kramer R, Neumann B, Haller S, Pfennigwerth N, Werner G, et al. Rapid spread of OXA-244-producing *Escherichia coli* ST38 in Germany: insights from an integrated molecular surveillance approach; 2017 to January 2020. *Euro Surveill*. 2020;25(25):2000923. <https://doi.org/10.2807/1560-7917.ES.2020.25.25.2000923> PMID: 32613940
- European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Increase in OXA-244-producing *Escherichia coli* in the European Union/European Economic Area and the UK since 2013. Stockholm: ECDC; 18 Feb 2020. Available from: <https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-increase-oxa-244-producing-escherichia-coli-eu-eea>
- Fursova NK, Astashkin EI, Knyazeva AI, Kartsev NN, Leonova ES, Ershova ON, et al. The spread of bla OXA-48 and bla OXA-244 carbapenemase genes among *Klebsiella pneumoniae*, *Proteus mirabilis* and *Enterobacter* spp. isolated in Moscow, Russia. *Ann Clin Microbiol Antimicrob*. 2015;14(1):46. <https://doi.org/10.1186/s12941-015-0108-y> PMID: 26526183
- Oteo J, Hernández JM, Espasa M, Fleites A, Sáez D, Bautista V, et al. Emergence of OXA-48-producing *Klebsiella pneumoniae* and the novel carbapenemases OXA-244 and OXA-245 in Spain. *J Antimicrob Chemother*. 2013;68(2):317-21. <https://doi.org/10.1093/jac/dks383> PMID: 23034714
- Hammerum AM, Porsbo LJ, Hansen F, Roer L, Kaya H, Henius A, et al. Surveillance of OXA-244-producing *Escherichia coli* and epidemiologic investigation of cases, Denmark, January 2016 to August 2019. *Euro Surveill*. 2020;25(18). <https://doi.org/10.2807/1560-7917.ES.2020.25.18.1900742> PMID: 32400363
- Falgenhauer L, Nordmann P, Imirzalioglu C, Yao Y, Falgenhauer J, Hauri AM, et al. Cross-border emergence of clonal

- lineages of ST38 *Escherichia coli* producing the OXA-48-like carbapenemase OXA-244 in Germany and Switzerland. *Int J Antimicrob Agents*. 2020;106157. <https://doi.org/10.1016/j.ijantimicag.2020.106157> PMID: 32919009
23. Emeraud C, Biez L, Girlich D, Jousset AB, Naas T, Bonnin RA, et al. Screening of OXA-244 producers, a difficult-to-detect and emerging OXA-48 variant? *J Antimicrob Chemother*. 2020;75(8):2120-3. <https://doi.org/10.1093/jac/dkaa155> PMID: 32363407
 24. Pitout JD. Extraintestinal pathogenic *Escherichia coli*: an update on antimicrobial resistance, laboratory diagnosis and treatment. *Expert Rev Anti Infect Ther*. 2012;10(10):1165-76. <https://doi.org/10.1586/eri.12.110> PMID: 23199402
 25. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill*. 2015;20(45):30062. <https://doi.org/10.2807/1560-7917.ES.2015.20.45.30062> PMID: 26675038
 26. Dahbi G, Mora A, Mamani R, López C, Alonso MP, Marzoa J, et al. Molecular epidemiology and virulence of *Escherichia coli* O16:H5-ST131: comparison with H30 and H30-Rx subclones of O25b:H4-ST131. *Int J Med Microbiol*. 2014;304(8):1247-57. <https://doi.org/10.1016/j.ijmm.2014.10.002> PMID: 25455219
 27. Mora A, Dahbi G, López C, Mamani R, Marzoa J, Dion S, et al. Virulence patterns in a murine sepsis model of ST131 *Escherichia coli* clinical isolates belonging to serotypes O25b:H4 and O16:H5 are associated to specific virotypes. *PLoS One*. 2014;9(1):e87025. <https://doi.org/10.1371/journal.pone.0087025> PMID: 24498015
 28. Matuschek E, Åhman J, Webster C, Kahlmeter G. Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Acinetobacter* spp. *Clin Microbiol Infect*. 2018;24(8):865-70. <https://doi.org/10.1016/j.cmi.2017.11.020> PMID: 2922199

License, supplementary material and copyright

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2020.